Merck unveiled another kind of HDL-raiser, a drug to inhibit the cholesterol ester transfer protein (CETP).

FORBES: Magazine Article

The clincher: Once a prototype drug works against one kinase, Vertex figures it can easily tweak the compound to inhibit other siblings in the kinase family--and then attack other protein groups, as well.

FORBES: Machine Gunner